©The Author(s) 2025.
World J Gastrointest Surg. Oct 27, 2025; 17(10): 111454
Published online Oct 27, 2025. doi: 10.4240/wjgs.v17.i10.111454
Published online Oct 27, 2025. doi: 10.4240/wjgs.v17.i10.111454
Figure 3 SLC39A14 expression and survival analysis in The Cancer Genome Atlas cohorting.
A: SLC39A14 expression in cancer patients (T) and normal individuals (N) (P < 0.05); B: Changes in SLC39A14 expression across cancer stages; C: Overall survival in male patients with high and low SLC39A14 expression (P = 0.017); D: Overall survival in female patients with high and low SLC39A14 expression (P = 0.2).
- Citation: Guo W, Wang MX, Mu T, Xu K, Jiang ZD, Wan XH, Li JW, Yi YX. Reduction in the hepatocellular carcinoma antioncogene SLC39A14 during the malignant progression of hepatocellular carcinoma. World J Gastrointest Surg 2025; 17(10): 111454
- URL: https://www.wjgnet.com/1948-9366/full/v17/i10/111454.htm
- DOI: https://dx.doi.org/10.4240/wjgs.v17.i10.111454